Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized or outpatient male or female, term or post-term infants beyond the neonatal period (\>28 days) but less than 12 months of age, OR a preterm infant with a corrected age of at least 44 weeks but less than 12 months on Dosing Day 1.~* Clinically-evident Gastroesophageal Reflux Disease (feeding intolerance, regurgitation, wheezing or stridor with feedings)~* At least 7 days post-surgery without anticipated need for surgery during study~* No significant laboratory abnormalities~Exclusion Criteria:~* Unstable, clinically significant disease or abnormality~* Congenital anomaly of the upper gastrointestinal tract~* Clinical evidence of acute sepsis~* Cystic fibrosis~* Medical condition requiring subject to not be fed by mouth/gastric tube

- Gender: ALL
- Minimum Age: 29 Days
- Maximum Age: 364 Days
- Healthy Volunteers: f

Study Arms:
- Lansoprazole 1.0 mg/kg QD (Type: EXPERIMENTAL): None
- Lansoprazole 2.0 mg/kg QD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).